Compare Stocks: SCPH, GLUE, KURA, and SANA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLUE Monte Rosa Therapeutics	$14.07 -1.7%	$18.05	$4.80 ▼ $25.77	$1.22B	1.5	995,057 shs	1.17 million shs
KURA Kura Oncology	$11.39 -1.6%	$11.23	$7.36 ▼ $13.90	$1.03B	0.44	2.25 million shs	2.12 million shs
SANA Sana Biotechnology	$3.13 +1.3%	$3.59	$2.61 ▼ $6.55	$925.02M	2.12	2.92 million shs	3.28 million shs
SCPH scPharmaceuticals	$5.67	$5.64	$2.20 ▼ $6.28	$302.20M	0.31	953,834 shs	N/A

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLUE Monte Rosa Therapeutics	+0.42%	-0.42%	-9.14%	-21.49%	+198.33%
KURA Kura Oncology	-4.30%	-12.02%	+16.52%	+27.85%	+41.62%
SANA Sana Biotechnology	-2.52%	-21.17%	-18.47%	+15.30%	+6.19%
SCPH scPharmaceuticals	0.00%	0.00%	0.00%	0.00%	+1.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GLUE Monte Rosa Therapeutics	$14.07 -1.7%	$18.05	$4.80 ▼ $25.77	$1.22B	1.5	995,057 shs	1.17 million shs
KURA Kura Oncology	$11.39 -1.6%	$11.23	$7.36 ▼ $13.90	$1.03B	0.44	2.25 million shs	2.12 million shs
SANA Sana Biotechnology	$3.13 +1.3%	$3.59	$2.61 ▼ $6.55	$925.02M	2.12	2.92 million shs	3.28 million shs
SCPH scPharmaceuticals	$5.67	$5.64	$2.20 ▼ $6.28	$302.20M	0.31	953,834 shs	N/A

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GLUE Monte Rosa Therapeutics	+0.42%	-0.42%	-9.14%	-21.49%	+198.33%
KURA Kura Oncology	-4.30%	-12.02%	+16.52%	+27.85%	+41.62%
SANA Sana Biotechnology	-2.52%	-21.17%	-18.47%	+15.30%	+6.19%
SCPH scPharmaceuticals	0.00%	0.00%	0.00%	0.00%	+1.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GLUE Monte Rosa Therapeutics	2.78	Moderate Buy	$28.50	102.56% Upside
KURA Kura Oncology	2.75	Moderate Buy	$25.40	123.00% Upside
SANA Sana Biotechnology	2.80	Moderate Buy	$9.33	198.19% Upside
SCPH scPharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest SCPH, GLUE, KURA, and SANA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/9/2026	GLUE Monte Rosa Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
8/25/2026	GLUE Monte Rosa Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$28.00
8/24/2026	KURA Kura Oncology	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$24.00
8/24/2026	KURA Kura Oncology	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/24/2026	GLUE Monte Rosa Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/24/2026	KURA Kura Oncology	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$24.00
8/24/2026	SANA Sana Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/14/2026	SANA Sana Biotechnology	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $6.00
8/13/2026	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $38.00
8/11/2026	GLUE Monte Rosa Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D+) ➝ Sell (D)

(Data available from 9/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GLUE Monte Rosa Therapeutics	$123.67M	9.71	N/A	N/A	$3.58 per share	3.93
KURA Kura Oncology	$67.48M	15.02	N/A	N/A	$2.00 per share	5.70
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.60 per share	N/A
SCPH scPharmaceuticals	$49.97M	6.05	N/A	N/A	$0.27 per share	21.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GLUE Monte Rosa Therapeutics	-$38.63M	-$1.76	N/A	N/A	N/A	-560.85%	-43.31%	-27.59%	11/5/2026 (Estimated)
KURA Kura Oncology	-$278.67M	-$3.37	N/A	N/A	N/A	-384.30%	-207.18%	-45.17%	11/3/2026 (Estimated)
SANA Sana Biotechnology	-$244.17M	-$0.76	N/A	N/A	N/A	N/A	-103.02%	-39.16%	11/5/2026 (Estimated)
SCPH scPharmaceuticals	-$85.15M	-$1.81	N/A	N/A	N/A	-183.55%	-1,647.86%	-71.76%	N/A

Latest SCPH, GLUE, KURA, and SANA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KURA Kura Oncology	-$0.8773	-$0.77	+$0.1073	-$0.77	$20.16 million	$20.87 million
8/10/2026	Q2 2026	SANA Sana Biotechnology	-$0.1469	-$0.13	+$0.0169	-$0.22	N/A	N/A
8/6/2026	Q2 2026	GLUE Monte Rosa Therapeutics	-$0.3805	-$0.43	-$0.0495	-$0.43	$12.91 million	$8.97 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
GLUE Monte Rosa Therapeutics	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A
SCPH scPharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GLUE Monte Rosa Therapeutics	N/A	10.58	10.58
KURA Kura Oncology	0.12	4.73	4.71
SANA Sana Biotechnology	N/A	1.38	1.38
SCPH scPharmaceuticals	N/A	3.85	3.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GLUE Monte Rosa Therapeutics	79.96%
KURA Kura Oncology	N/A
SANA Sana Biotechnology	88.23%
SCPH scPharmaceuticals	89.52%

Insider Ownership

Company	Insider Ownership
GLUE Monte Rosa Therapeutics	6.40%
KURA Kura Oncology	7.60%
SANA Sana Biotechnology	25.40%
SCPH scPharmaceuticals	4.78%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GLUE Monte Rosa Therapeutics	90	85.31 million	79.85 million	Optionable
KURA Kura Oncology	130	88.96 million	82.20 million	Optionable
SANA Sana Biotechnology	380	299.36 million	223.32 million	Optionable
SCPH scPharmaceuticals	30	53.30 million	50.75 million	Optionable

SCPH, GLUE, KURA, and SANA Headlines

Recent News About These Companies

scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of ...

June 24, 2026 | stockhouse.com

MannKind (MNKD) Is Up 25.4% After Mixed Q1 Results and Expanded United Therapeutics Partnership – What's Changed

May 8, 2026 | finance.yahoo.com

scPharmaceuticals Inc. Common Stock (SCPH)

April 17, 2026 | nasdaq.com

MannKind initiated with a Buy at Truist

November 24, 2025 | msn.com

MannKind (MNKD): Evaluating Valuation After Strong Q3 Revenue Beat and Pipeline Expansion

November 8, 2025 | finance.yahoo.com

MannKind Stock Soared 8% Today: Why A Surge In Afrezza Inhaled Insulin Sales Matters

November 5, 2025 | msn.com

MannKind outlines FUROSCIX market expansion and Afrezza pediatric launch strategy following record $82M Q3 revenue

November 5, 2025 | msn.com

MannKind completes acquisition of scPharmaceuticals

October 7, 2025 | msn.com

scPharmaceuticals Completes Merger and Delists from Nasdaq

October 7, 2025 | msn.com

scPharmaceuticals Issues Promissory Note to MannKind

September 25, 2025 | msn.com

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

September 16, 2025 | businesswire.com

Corstasis scores FDA nod for nasal spray treatment, touts sales potential

September 15, 2025 | fiercepharma.comF

MannKind diversifies pipeline with $360M buy

September 2, 2025 | pacbiztimes.comP

H.C. Wainwright Reiterates a Buy Rating on MannKind Corporation (MNKD)

August 31, 2025 | finance.yahoo.com

scPharmaceuticals downgraded to Hold from Buy at Maxim

August 26, 2025 | msn.com

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...

August 26, 2025 | tmcnet.com

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

August 26, 2025 | businesswire.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTLE and SCPH on Behalf of Shareholders

August 26, 2025 | globenewswire.com

scPharmaceuticals downgraded to Hold from Buy at Craig-Hallum

August 25, 2025 | msn.com

CT maker of therapeutic inhalers agrees to acquire Mass. biopharma company in $360M deal

August 25, 2025 | hartfordbusiness.comH

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCPH, GLUE, KURA, and SANA Company Descriptions

Monte Rosa Therapeutics NASDAQ:GLUE

$14.07 -0.25 (-1.75%)

Closing price 04:00 PM Eastern

Extended Trading

$14.08 +0.00 (+0.04%)

As of 07:39 PM Eastern

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Kura Oncology NASDAQ:KURA

$11.39 -0.18 (-1.56%)

Closing price 04:00 PM Eastern

Extended Trading

$11.45 +0.06 (+0.53%)

As of 07:40 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Sana Biotechnology NASDAQ:SANA

$3.13 +0.04 (+1.29%)

Closing price 04:00 PM Eastern

Extended Trading

$3.15 +0.02 (+0.64%)

As of 07:56 PM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

scPharmaceuticals NASDAQ:SCPH

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SCPH, GLUE, KURA, and SANA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SCPH, GLUE, KURA, and SANA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SCPH, GLUE, KURA, and SANA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCPH, GLUE, KURA, and SANA Company Descriptions

Monte Rosa Therapeutics NASDAQ:GLUE

Kura Oncology NASDAQ:KURA

Sana Biotechnology NASDAQ:SANA

scPharmaceuticals NASDAQ:SCPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SCPH, GLUE, KURA, and SANA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SCPH, GLUE, KURA, and SANA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SCPH, GLUE, KURA, and SANA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCPH, GLUE, KURA, and SANA Company Descriptions

Monte Rosa Therapeutics NASDAQ:GLUE

Kura Oncology NASDAQ:KURA

Sana Biotechnology NASDAQ:SANA

scPharmaceuticals NASDAQ:SCPH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools